Dipna Pharmachem Limited is an India-based trader, importer, and exporter in industrial chemical and pharmaceutical raw materials, active pharmaceutical ingredients (APIs), solvents, and formulation. The Company is primarily engaged in a single segment, which is pharmaceutical trading. Its products include aceclofenac, acetazolamide, albendazole, ambroxol hcl, amisulpride ip/bp, amoxicillin aripiprazole ip, azithromycin, cefixime, carbamezapin, calcium gluconate ip, cefadroxyl monohydrate ip/bp/ep cephalexin, clindamycin phosphate ip/bp/usp, clotrimazole, cetrimide powder, chlorhexidine base, chlorhexidine hydrochloride, Bronopol, cm-1000, calcium cmc, calcium carbonate (light), calcium carbonate (oys), ceto stearyl alcohol, citric acid (anhydrous), and citric acid (monohydrate). It also provides assistance in setting up contract manufacturing compliance for regulated and semi-regulated pharmaceutical companies with all the global benchmark parameters of certificates like WHO-GMP.
DIPNA PHARMACHEM LIMITED Financial Highlights
- Revenue: DIPNA PHARMACHEM LIMITED reported revenue of ₹129.11 crore in FY26 vs ₹124.93 crore in FY25. It showed an increase of 3.35% on a yearly basis.
- Operating Profit: DIPNA PHARMACHEM LIMITED reported an operating profit of ₹3.54 crore in FY26 vs ₹1.42 crore in FY25. It showed an increase of 149.30% on a year-on-year basis.
- Net Profit: DIPNA PHARMACHEM LIMITED reported a net profit of ₹2.63 crore in FY26 vs ₹0.97 crore in FY25. It showed an increase of 171.13% on a yearly basis.
DIPNA PHARMACHEM LIMITED Quarterly Result Highlights
- DIPNA PHARMACHEM LIMITED reported revenue of ₹2.05 crore in Mar 2026, compared with ₹53.52 crore in Dec 2025, representing a decrease of 96.17% on a quarter-on-quarter (QoQ) basis.
- DIPNA PHARMACHEM LIMITED reported an operating profit of ₹0.22 crore in Mar 2026, compared with ₹1.42 crore in Dec 2025, representing a decrease of 84.51% on a quarter-on-quarter (QoQ) basis.
- DIPNA PHARMACHEM LIMITED reported a profit of ₹0.18 crore in Mar 2026, compared with ₹1.04 crore in Dec 2025, reflecting a decrease of 82.69% on a QoQ basis.
- The earnings per share (EPS) of DIPNA PHARMACHEM LIMITED stood at ₹0.41 during Mar 2026.